Literature DB >> 8557006

Structure-pharmacodynamic-pharmacokinetic relationships of steroidal neuromuscular blocking agents.

J M Wierda1, J H Proost.   

Abstract

Several new steroidal non-depolarizing muscle relaxants have been synthesized and tested in humans recently. Results from these studies suggest that the differences in time-course of action between these compounds are mainly, if not totally, related to differences in biodisposition. Biodisposition, in turn, is determined largely by the physico-chemical characteristics of the drug, such as degree of lipophilicity and protein binding. The various pharmacodynamic and pharmacokinetic variables of a series of structurally related steroidal relaxants, varying in the ester substituent at the 17th position of the androstane skeleton, have been related to the degree of lipophilicity. Significant positive relationships could be shown between lipophilicity (logP at pH 7.4) and, among other things, potency (ED90), effective concentration (EC50), unbound plasma clearance (CLupl) and rate constant of transport between plasma and biophase (ke0). The aforementioned relationships between lipophilicity and pharmacokinetic variables resulted in significant inverse relationships between lipophilicity and time course parameters, such as onset time and duration of neuromuscular blocking effects. It is concluded that changes in the molecular structure of steroidal relaxants which enhance lipophilicity coincide with a decrease of (intrinsic) potency and a shorter time course of action. Protein binding appears to be of minor importance for the biodisposition and time course characteristics, since there were only small differences in degree of protein binding between most of the investigated compounds. However, the surprisingly fast initial rate of block development observed with rocuronium may in part result from its relatively high unbound fraction in plasma.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8557006

Source DB:  PubMed          Journal:  Eur J Anaesthesiol Suppl        ISSN: 0952-1941


  5 in total

Review 1.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Rapacuronium bromide: a review of its use in anaesthetic practice.

Authors:  S V Onrust; R H Foster
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 3.  Pharmacokinetics and pharmacodynamics of rapacuronium bromide.

Authors:  William J Wight; Peter M C Wright
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Neuromuscular transmission and its pharmacological blockade. Part 2: Pharmacology of neuromuscular blocking agents.

Authors:  L H Booij
Journal:  Pharm World Sci       Date:  1997-02

5.  Influence of obstructive jaundice on pharmacodynamics of rocuronium.

Authors:  Zhen-Meng Wang; Peng Zhang; Mi-Jia Lin; Bo Tan; Hai-Bo Qiu; Wei-Feng Yu
Journal:  PLoS One       Date:  2013-10-16       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.